Schizophrenia Clinical Trials

Find Schizophrenia Clinical Trials Near You

The Impact of Social Isolation on Aging Health in Schizophrenia

Status: Recruiting
Location: See all (4) locations...
Study Type: Observational
SUMMARY

Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors. Remarkably, the direct adverse health effects of key clinical characteristics of SZ have rarely been considered. In the general population, the absence of social contact is known to pose enormous challenges for physical health, especially at older ages. Given that social isolation is a persistent and disabling feature of SZ, it is possible that this behavior may contribute to the premature manifestation of health conditions in SZ. Building on rich pilot data pointing to significant associations between social isolation and long-term perceived health in SZ, the overarching goal is to test whether and how social isolation contributes to the health challenges of individuals with SZ as they age. With participants from Europe (EU-GEI) and the US (Olin Neuropsychiatry Research Center), the researchers will create a longitudinal database of 650 participants, including 500 individuals with SZ, and 150 of their unaffected siblings. The researchers will apply an accelerated longitudinal design by reassessing and by examining medical records of research participants who were first evaluated between the ages of 20-55 and are now 40-70 years of age, a period when many medical conditions and health problems tend to manifest. The researchers will determine the age-related association between social isolation and adverse health outcomes in SZ, test for familiality, directionality, and factors moderating this association, and determine the extent to which the COVID-19 pandemic and the resulting imposed lockdowns impacted health in SZ. The researchers will consider generalizability across countries, sexes, and race/ethnicities. The rationale for the proposed research is that in order to facilitate much-needed targeted therapies to prevent early mortality in SZ, the researchers need to better understand factors that contribute to the excess of medical comorbidities in SZ. The central hypothesis is that social isolation, a common and persistent characteristic of SZ, contributes to the excess of physical comorbidities in SZ. To meet the overall goal, the following aims are: (1) Determine the association between social isolation and adverse health outcomes in SZ; (2) Test for the directionality, and moderating factors, of the association between social isolation and health outcomes in SZ, and; (3) Examine whether the COVID-19 pandemic modified associations between social isolation and health outcome in SZ. This study will be the first to comprehensively examine the health impact of social isolation in SZ. The project may show that in SZ socialization in midlife can reduce the risk for poor health outcomes and ultimately facilitate much-needed preventive targeted therapies to reduce early-age mortality in SZ

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
Healthy Volunteers: t
View:

• DSM-IV or V diagnosis of a SZ related disorder (295.x, 297.1, 298.8, or 298.9; e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, but not psychotic disorder that is solely substance induced) based on clinical interview;

• Between 40 and 70 years of age at time of study recruitment;

• Participant was enrolled in a previous research study between the ages of 20-55, and this study took place at least 5 years ago;

• Able to understand the spoken language of the participating country sufficiently to comprehend testing procedures;

• No history of serious head injury (i.e., loss of consciousness longer than 1 hour, no neuropsychological sequelae, no cognitive rehabilitation treatment post head injury);

• No history of IQ \< 70, or developmental disability based on chart review;

• Clinically stable (i.e., no inpatient hospitalizations for three months prior to enrollment, no changes in medication in the four weeks prior to enrollment;

Locations
United States
Connecticut
Olin Neuropsychiatry Research Center, Hartfort
RECRUITING
Hartford
Other Locations
Netherlands
AUMC, University Hospital
RECRUITING
Amsterdam
Spain
Hospital General Universitario Gregorio Marañon
RECRUITING
Madrid
United Kingdom
King's College London
RECRUITING
London
Contact Information
Primary
Eva Velthorst, PhD
e.velthorst@ggz-nhn.nl
+31618644345
Time Frame
Start Date: 2024-01-09
Estimated Completion Date: 2027-07
Participants
Target number of participants: 650
Treatments
Individuals with SZ
Individuals with a schizophrenia-related diagnosis
Unaffected first-degree relatives
Unaffected first-degree relatives of individuals with a schizophrenia-related diagnosis
Related Therapeutic Areas
Sponsors
Collaborators: Hospital General Universitario Gregorio Marañon, Yale University, Karolinska Institutet, Hartford Hospital, University of Miami, Boston Children's Hospital, National Institute of Mental Health (NIMH), Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), GGZ Noord-Holland-Noord, King's College London
Leads: Icahn School of Medicine at Mount Sinai

This content was sourced from clinicaltrials.gov